Results 111 to 120 of about 2,239,865 (298)

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

open access: yesMolecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim   +11 more
wiley   +1 more source

ANOVA table.

open access: yes, 2019
ANOVA table.
Débora Zurro (719094)   +5 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Strengthening primary care mental health services – lessons from the South African HIV programme

open access: yesSouth African Medical Journal
-
J Dunlop   +8 more
doaj   +1 more source

ANOVA Results.

open access: yes, 2016
ANOVA Results.
Marilyn E. Brandt (380258)   +4 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

ANOVA statistics.

open access: yes, 2015
ANOVA statistics.
Emily P. Zefferman (705916)
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

El model ANOVA unifactorial

open access: yes, 2020
The one-factor ANOVA modelEl modelo ANOVA unifactorialEl model ANOVA unifactorial7936.mp4 7936 ...

core   +2 more sources

Healthcare needs and barriers to care among female partners of male suspects of child sexual abuse material offences in Sweden: a qualitative interview study

open access: yesFrontiers in Psychiatry
ObjectiveTo explore the impact on female partners of the discovery that their significant other is under investigation for Child Sexual Abuse Material (CSAM) offences, with a focus on the need for professional support.DesignSemi-structured interviews ...
Roberth Adebahr   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy